Pseudoephedrine

證據等級: L5

預測適應症: 3 個

Pseudoephedrine: From Nasal Decongestant to Nasal Cavity Disease

One-Sentence Summary

Pseudoephedrine (DrugBank DB00852) is an oral α-adrenergic agonist long used as a systemic nasal decongestant. The TxGNN model predicts high relevance for Nasal Cavity Disease (score 99.75%), supported by 19 clinical trials (1 rated directly relevant) and 7 publications identified in this search. Note: this largely confirms an already-established pharmacological use rather than revealing a genuinely novel indication.

Quick Overview

Item	Content
Original Indication	Not on file in SAHPRA licensing data (drug not currently registered in South Africa); pharmacologically established as an oral systemic nasal decongestant per the evidence rationale
Predicted New Indication	Nasal Cavity Disease
TxGNN Prediction Score	99.75%
Evidence Level	L2
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed formal mechanism-of-action documentation (e.g., a DrugBank MOA monograph entry) is not available in this evidence pack. Based on the pharmacological rationale captured alongside the prediction, pseudoephedrine is an α-adrenergic agonist that acts directly on α1 receptors in the vascular smooth muscle of the nasal mucosa, producing vasoconstriction that reduces mucosal congestion and swelling. This is the classic mechanism of an oral, systemically-acting nasal decongestant.

Because this mechanism directly targets nasal mucosal blood flow, the high TxGNN score (0.9975) for “nasal cavity disease” is mechanistically unsurprising — it converges with pseudoephedrine’s long-standing real-world use rather than pointing to a truly novel therapeutic application. Clinicians should read this prediction as confirmatory validation of known pharmacology, not as a discovery of new drug-disease biology.

Two lower-ranked TxGNN predictions for this drug — acute laryngopharyngitis (L5, no supporting trials or literature) and allergic urticaria (L4, indirect evidence only from combination products) — were reviewed but are not carried forward in this report given weak or absent supporting evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00562120	Phase 2	Completed	21	Double-blind, double-dummy, 4-way crossover in seasonal allergic rhinitis testing an H3-antagonist decongestant effect via acoustic rhinometry after nasal allergen challenge; directly relevant to nasal decongestion pharmacology (relevance grade A)
NCT00804687	Phase 2	Completed	53	Randomized, single-blind, double-dummy, 3-way crossover directly comparing JNJ-39220675 vs. pseudoephedrine vs. placebo for allergic rhinitis in an environmental exposure chamber
NCT00015795	Phase 1	Completed	30	Airflow/laryngeal resistance study in abductor spasmodic dysphonia; low relevance, disease-area overlap only (grade C)
NCT03979209	Phase 1	Completed	16	Cortisol suppression risk with high-volume nasal mometasone irrigation; different drug class (corticosteroid), disease-area overlap only (grade C)
NCT00939393	N/A	Completed	72	Endoscopic sinus surgery performed in-office vs. operating room; surgical, not a drug trial (grade C)
NCT04048174	N/A	Completed	27	Probiotic bacteria (L. lactis) for chronic rhinosinusitis refractory to standard therapy; unrelated mechanism (grade C)
NCT04645511	N/A	Recruiting	120	Balloon sinuplasty vs. placebo in chronic/recurrent maxillary rhinosinusitis; device, not drug (grade C)
NCT05494346	N/A	Recruiting	101	Decongestant seawater spray device with essential oils for acute rhinitis; device, not oral decongestant (grade C)
NCT06010316	N/A	Unknown	200	Prospective cohort on surgical treatment of chronic rhinosinusitis; disease-area overlap only (grade C)
NCT03725956	N/A	Unknown	30	Endoscopic sinus surgery effect on sleep disorder in nasal polyposis; surgical, not a drug trial (grade C)

Note: Only the first two trials directly test pseudoephedrine or a comparable decongestant mechanism. The remaining eight (all graded “C” — low relevance) are included for completeness because they share the nasal cavity disease area, but represent surgical, device, or unrelated-drug interventions, not pharmacological evidence for pseudoephedrine itself.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
11345158	2001	Comparative human study	American Journal of Rhinology	Direct human comparison of oral phenylpropanolamine vs. d-pseudoephedrine decongestant effect using acoustic rhinometry to measure nasal cavity dimensions
22794679	2012	Review	Allergy and Asthma Proceedings	Review chapter on nonallergic rhinitis pathophysiology and management, contextualizing decongestant therapy
19769798	2009	Animal model (feline)	American Journal of Rhinology & Allergy	Feline model showing decongestant action of D-pseudoephedrine alone and combined with desloratadine
24492651	2014	Animal model (pharmacological evaluation)	Journal of Pharmacology and Experimental Therapeutics	Pharmacological characterization of α2c-adrenergic agonists in animal nasal congestion models, contextual to adrenergic decongestant mechanism
12962193	2003	Animal model (canine)	American Journal of Rhinology	Canine ragweed-sensitized allergic nasal congestion model using acoustic rhinometry
12387934	2002	Animal model (canine)	Journal of Pharmacological and Toxicological Methods	Chronic canine model developed to study nasal decongestant drug mechanisms
11895194	2002	Animal model (canine)	American Journal of Rhinology	Acoustic rhinometry validation in a canine model of nasal congestion

South Africa Market Information

Pseudoephedrine is not currently registered or marketed in South Africa according to the data available (0 SAHPRA registrations on file). No product/registration-level information can be reported.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic link is strong and well-established (α1-adrenergic vasoconstriction of nasal mucosa), and one directly relevant Phase 2 comparative trial exists (NCT00804687), supporting an L2 evidence level. However, this largely reconfirms pseudoephedrine’s known decongestant use rather than a novel indication, and a Blocking data gap exists: SAHPRA-approved PI warnings/contraindications are not yet available, which prevents a full safety (S1) evaluation.

To proceed, the following is needed:

SAHPRA-approved Professional Information (PI) — warnings and contraindications (Blocking gap; required before safety sign-off)
Formal DrugBank/manufacturer mechanism-of-action documentation
Confirmation of whether a South African registration/import pathway is being pursued, since the drug is currently unmarketed locally
Drug-drug interaction review, given the “not_found” DDI query status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.